Celestica (CLS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Celestica is downgraded to Hold from Buy due to limited upside and stretched valuation after a strong rally. CLS's business momentum remains robust, driven by rapid growth in its High-Performance ...

CLS' beneficiary status during the ongoing AI and data center boom is undeniable, with the growing hyperscaler capex already flowing into its expanding top/ bottom-lines. The management has further ...

Street expects another big quarter: $3.04B revenue and $1.49 EPS, with FY2025 EPS seen rising 45% YoY. Celestica will hold its conference call at 8 AM tomorrow morning. You can register to listen in ...

What makes student residents remember a space? It’s personalization, argues Elliot Tamir, co-founder & co-CEO of CLS Living. That individual attention needs to come through in their daily experience.

We recently published Monstrous Gains: 10 Stocks Leaving Wall Street in the Dust. Celestica Inc. (NYSE:CLS) is one of the best performers on Friday. Celestica soared to a new all-time high on Friday, ...

The US subsea cable landing station (CLS) for the US-Singapore Bifrost cable system has gone live in Oregon. Flexential this week announced that the Bifrost Cable System’s CLS in Winema, Oregon, which ...

Google announced its earnings after the market closed on Tuesday. While its stock is plummeting, the company did forecast data center spending well beyond Wall Street’s expectations. Nvidia made early ...

Celestica Inc. CLS has gained a phenomenal 241.8% over the past year compared with the electronics manufacturing services industry’s growth of 54.4%. It has also outperformed peers like Flex Ltd. FLEX ...

Google Web Performance Advocate clarifies Cumulative Layout Shift (CLS) measurement, aiding web developers in optimizing Core Web Vitals. Google's Web Performance Advocate, Barry Pollard, provides ...

Performances in N.Y.C. Advertisement Supported by A diner patron asks a waitress for an extraordinary side dish in Meghan Kennedy’s sweet but shaggy new play. By Jesse Green With their twirly stools, ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected for a variety of common eye diseases, Clearside Biomedical is making ...